Pseudohypoaldosteronism

Total Page:16

File Type:pdf, Size:1020Kb

Load more

Arch Dis Child: first published as 10.1136/adc.55.6.427 on 1 June 1980. Downloaded from Archives of Disease in Childhood, 1980, 55, 427-434 Pseudohypoaldosteronism M J DILLON, J V LEONARD, J M BUCKLER, D OGILVIE, D LILLYSTONE, J W HONOUR, AND C H L SHACKLETON The Hospitalfor Sick Children and Queen Elizabeth Hospital for Children, London, Department of Paediatrics and Child Health, University ofLeeds, and Division of Clinical Chemistry, Clinical Research Centre, Harrow, Middlesex SUMMARY 10 infants are described with pseudohypoaldosteronism, 5 in detail and a further 5 briefly. They all presented with hyperkalaemia, urinary salt-wasting disease, and ostensibly normal renal and adrenocortical function. Diagnosis was established by demonstrating the greatly increased values of plasma renin activity and plasma aldosterone concentration, plus the increased excretion of aldosterone and its metabolites on gas chromatographic and mass spectrometric analyses of urine. The children were treated with sodium chloride supplements, up to 60 mmol/day, but by the time most ofthe infants were about a year old these could be stopped. Exogenous mineralocorticoids were without effect in those to whom they were administered. The precise aetiology of the condition remains conjectural; lack of renal tubular response to aldosterone seems probable. Pseudohypo- aldosteronism may be more common than has been thought and new techniques for investigating salt-wasting disorders may show its true incidence. Salt loss in infancy is often due to gastrointestinal This paper describes in detail 5 more children with disease and in such cases there is renal conservation PHA, and briefly refers to a further 5 cases in whom of sodium. In contrast, urinary salt loss occurs in diagnostic investigations were undertaken in our certain renal tubular disorders and in adrenal laboratories. The diagnosis was established in all 10 insufifciency. Severe salt loss in infancy has been children by the characteristic increase in plasma described despite ostensibly normal renal and renin and aldosterone levels, and in most children http://adc.bmj.com/ adrenocortical function, and has been attributed by the typical urinary corticosteroid findings. to lack of response of the renal tubule to endo- genous mineralocorticoids. This syndrome has been Methods called pseudohypoaldosteronism and since 1958, when it was first described by Cheek and Perry,' PRA and PAldo concentration were measured using 30 cases have been described.2-19 In one report20 the methods of Dillon,22 and Dillon and Ryness.23 7 additional but atypical cases were described and on October 1, 2021 by guest. Protected copyright. these patients were shown subsequently to have a defect of aldosterone biosynthesis.2' Abbreviations: The Hospital for Sick Children, London PHA: pseudohypoaldosteronism M J DILLON, consultant paediatrician PRA: plasma renin activity Institute of Child Health, London PAldo: plasma aldosterone J V LEONARD, senior lecturer in child health D OGILVIE, research fellow GC: gas chromatography Department of Paediatrics and Child Health, GC/MS: gas chromatographic and mass University of Leeds spectrometric J M BUCKLER, senior lecturer in paediatrics 17-OS: 17-oxosteroids Hornsby and District Hospital, Hornsby, Sydney, Australia 11-01: 11-oxygenation index D LILLYSTONE, consultant paediatrician 17-OHP: 17-hydroxyprogesterone Division of Clinical Chemistry, Clinical Research Centre, ACTH: adrenocorticotropic hormone Harrow, Middlesex 9FC: 9oc-fludrocortisone J W HONOUR, senior research officer Biomedical Mass Spectrometry Resource, Space Sciences DOCA: desoxycorticosterone Laboratory, University of California, Berkeley, USA ATP: adenosine triphosphate C H L SHACKLETON, deputy director 427 Arch Dis Child: first published as 10.1136/adc.55.6.427 on 1 June 1980. Downloaded from 428 Dillon, Leonard, Buckler, Ogilvie, Lillystone, Honour, and Shackleton Urinary metabolites of cortisol and corticosterone but extremely high excretions of allo-tetrahydro- were analysed by capillary GC.24 Tetrahydroaldo- corticosterone, tetrahydroaldosterone, and 18- sterone and 18-hydroxytetrahydroCompound A hydroxytetrahydroCompound A were noted (Table). were analysed simultaneously by a GC/MS analysis It was possible gradually to reduce the treatment selected ion monitoring method.2526 Plasma and with corticosteroids without relapse, and later the urine electrolytes were measured simultaneously salt supplements were tailed off. By age one year our by flame photometry in a 5-channel autoanalyser. patient was well and was receiving no treatment. He Standard methods were used to estimate urine 17- is now 5 years and is catching up in growth; he has a hydroxycorticoids,27 17JS,28 pregnanetriol,29 and normal blood pressure, and can tolerate salt the 11-OI.30 Competitive protein-binding methods deprivation even when stressed by illness. were used to determine plasma cortisol,3' 17-OHP,32 and 11-deoxycortisol.33 Plasma ACTH was deter- Case 2. This girl was the fifth child of unrelated mined by radioimmunoassay.34 English parents. Her birth was normal and she weighed 3 04 kg. At 7 days she had been found in a Case reports collapsed state and on admission to hospital was moribund. She was resuscitated with intravenous fluids, antibiotics, and hydrocortisone as the pre- Case 1. This boy was the second child of unrelated sumptive diagnosis was septicaemia. The initial English parents. He was born normally at term response was satisfactory, but the next day her weighing 2 75 kg and since birth he had had re- condition deteriorated with pronounced electrolyte current episodes of vomiting. At 9 weeks he was imbalance despite intravenous fluids (plasma Na admitted to hospital because of a severe episode of 125 mmol/l, K 8-4 mmol/l). Congenital adrenal vomiting associated with dehydration. Plasmasodium hyperplasia was suspected although her genitalia (Na) was 118 mmol/l and potassium (K) 5 0 mmol/l. were normal; she was treated with DOCA, hydro- A presumptive diagnosis of salt-losing congenital cortisone, salt supplements, and an ion-exchange adrenal hyperplasia was made and he was treated resin. Several days later her condition again deterior- with intravenous fluids and intramuscular hydro- ated, plasma Na falling to 125 mmol/l and K rising cortisone. After more vomiting associated with to 8 2 mmol/l. At this stage PRA was 107 300 ng hyponatraemia, 9FC was given orally but his Al/I per hour and PAldo concentration much symptoms persisted. greater than 3000 pmol/l (Table). Plasma electro- Despite the treatment with mineralocorticoids the lytes failed to improve until she was given 60 mmol/ salt-losing state persisted; therefore 9FC was day NaCl in addition to hydrocortisone and DOCA. stopped and sodium chloride (NaCl) supplements She developed pneumonia, superimposed cardiac http://adc.bmj.com/ (50 mmol/day) were started. He became hyper- failure, and generalised convulsions. With intensive tensive (140/110 mmHg) and remained so when the treatment she recovered and was finally stabilised on NaCl supplements were withdrawn, although he 50 mmol/day NaCl. went into negative Na balance and plasma Na Standard tests of renal function, including intra- fell to 125 mmol/l. Plasma Na values were venous pyelography, gave results that were within eventually stabilised above 130 mmol/l with Na normal limits. Adrenal function tests including supplements of 60 and the mmol/day, blood pressure plasma 17-OHP, plasma cortisol, plasma 11- on October 1, 2021 by guest. Protected copyright. slowly returned to normal. Because of the persistent deoxycortisol, urine 17-oxogenic steroids, urine hypertension, PRA, and PAldo concentration were 17-OS, and urine pregnanetriol were essentially measured. PRA was 81 000 ng Al/I per hour normal before and after ACTH stimulation. (reference range for age, 472-3130 ng Al /1 per hour), She has maintained satisfactory progress. Her and PAldo concentration was considerably greater blood pressure remained normal on treatment. She than 3000 pmol/l (reference range for age, 160-3000 was discharged from hospital at 2 months on corti- pmol/l) (Table). sone 10 mg twice daily, 9FC 0 1 mg daily, and 25 Standard tests of renal function (including intra- mmol/day of added NaCl. The 9FC was stopped at venous pyelography) all gave results that were age 10 months and the cortisone withdrawn by 13 within normal limits. Adrenal function tests in- months. Aged 41 years, although small, she has cluding plasma 17-OHP, plasma cortisol, plasma grown normally with height and weight following 11-deoxycortisol, urine 17-OS, and urine 11-OI, the 3rd centile. GS/MS analysis of urinary cortico- before and after ACTH stimulation were essentially steroids at 21 years showed only moderately raised normal. GC/MS analyses of urinary corticosteroids tetrahydroaldosterone and 18.hydroxytetrahydro- were carried out on day 5 of the ACTH stimulation Compound A. Secretion of cortisol metabolites was test. Cortisol metabolites were moderately raised normal for age. Arch Dis Child: first published as 10.1136/adc.55.6.427 on 1 June 1980. Downloaded from Pseudohypoaldosteronism 429 80 °| za 0 Z |0 2 z 00 o 0%al 0o 0O] I) A aO a 110 Cli _-I .09 in - 00 E ~00 _lC C4 L.C 88 .0l en |0 A o V 0% 0 l 00 E - %O 00 R E% 0008° A 00oo tn> .04 01 88§ in Z O 9 C 0 Cl 00 O 0_ cl_ 0 00 Cq o w0 o I- 0 .. 0ZI E0 Cq) 01 Cl 0 E0 VE _ C.-000 oocoo 3 0 00%O -00 00 Cl V t Xl X 0. 88u 0.. enE %iD tn http://adc.bmj.com/ 00 0% enA a a %0O 0. oo 2 ZO Z 'ogo 004 0> %O t.- oo en C.) 00 ChN 0r- A0 0 Cl4 A 00 .-4 0 on October 1, 2021 by guest. Protected copyright. QW U 9 co a. t-00 en A z ~z C.) o E 11 2: Arch Dis Child: first published as 10.1136/adc.55.6.427 on 1 June 1980. Downloaded from 430 Dillon, Leonard, Buckler, Ogilvie, Lillystone, Honour, and Shackleton Case 3.
Recommended publications
  • Original Article Clinical Characteristics and Mutation Analysis of Two Chinese Children with 17A-Hydroxylase/17,20-Lyase Deficiency

    Original Article Clinical Characteristics and Mutation Analysis of Two Chinese Children with 17A-Hydroxylase/17,20-Lyase Deficiency

    Int J Clin Exp Med 2015;8(10):19132-19137 www.ijcem.com /ISSN:1940-5901/IJCEM0013391 Original Article Clinical characteristics and mutation analysis of two Chinese children with 17a-hydroxylase/17,20-lyase deficiency Ziyang Zhu, Shining Ni, Wei Gu Department of Endocrinology, Nanjing Children’s Hospital Affiliated to Nanjing Medical University, Nanjing 210008, China Received July 25, 2015; Accepted September 10, 2015; Epub October 15, 2015; Published October 30, 2015 Abstract: Combined with the literature, recognize the clinical features and molecular genetic mechanism of the disease. 17a-hydroxylase/17,20-lyase deficiency, a rare form of congenital adrenal hyperplasia, is caused by muta- tions in the cytochrome P450c17 gene (CYP17A1), and characterized by hypertension, hypokalemia, female sexual infantilism or male pseudohermaphroditism. We presented the clinical and biochemical characterization in two patients (a 13 year-old girl (46, XX) with hypokalemia and lack of pubertal development, a 11 year-old girl (46, XY) with female external genitalia and severe hypertension). CYP17A1 mutations were detected by PCR and direct DNA sequencing in patients and their parents. A homozygous mutation c.985_987delTACinsAA (p.Y329KfsX418) in Exon 6 was found in patient 1, and a homozygous deletion mutation c.1459_1467delGACTCTTTC (p.Asp487_Phe489del) in exon 8 in patient 2. The patients manifested with hypertension, hypokalemia, sexual infantilism should be sus- pected of having 17a-hydroxylase/17,20-lyase deficiency. Definite diagnosis is depended on mutation analysis. Hydrocortisone treatment in time is crucial to prevent severe hypertension and hypokalemia. Keywords: 17a-hydroxylase/17,20-lyase deficiency Introduction patients with 17a-hydroxylase/17,20-lyase defi- ciency, and made a confirmative diagnosis by Deficiency in cytochrome p450c17 (MIM mutation analysis of CYP17A1.
  • Congenital Hypoaldosteronism Developmental Delay

    Congenital Hypoaldosteronism Developmental Delay

    CASE REPORTS Congenital Hypoaldosteronism developmental delay. She had an episode of generalized seizures at 3 months of age. At presentation she weighed 4 kg with a head VANATHI SETHUPATHI, circumference of 35 cm and was severely VIJAYAKUMAR M dehydrated. Blood pressure was in the normal range LALITHA JANAKIRAMAN* for the age. She had partial head control with no NAMMALWAR BR grasp or social smile. Fundoscopy was normal. Liver was enlarged. External genitalia were normal. Initial hematological and biochemical values are shown in Table I. Urine metabolic screen, blood ammonia, ABSTRACT serum lactate, thyroid function, immunoglobulin, Congenital hypoaldosteronism due to an isolated complement levels and chest X-ray were normal. aldosterone biosynthesis defect is rare. We report a 4 Blood and urine cultures were negative. month old female infant who presented with failure to Ultrasonogram of the abdomen showed mild thrive, persistent hyponatremia and hyperkalemia. hepatomegaly with normal echotexture. Investigations revealed normal serum 17 hydroxy progesterone and cortisol. A decreased serum aldosterone Hyponatremia, hypercalemia and low serum and serum 18 hydroxy corticosterone levels with a low 18 bicarbonate was treated with intravenous calcium hydroxy corticosterone: aldosterone ratio was suggestive gluconate, sodium bicarbonate and oral sodium of corticosterone methyl oxidase type I deficiency. She was polystyrene sulfonate. During follow-up, serum started on fludrocortisone replacement therapy with a sodium continued to remain at around 125 mEq/L, subsequent normalization of electrolytes. Further molecular analysis is needed to ascertain the precise potassium varied between 6.2 and 7.2 mEq/L with nature of the mutation. bicarbonate around 18 mEq/L. The child was hospitalized twice subsequently for dehydration, Key words: Congenital hypoaldosteronism, CMO I defi- hyponatremia and hyperkalemia.
  • Primary Hyperaldosteronism: a Case of Unilateral Adrenal Hyperplasia with Contralateral Incidentaloma Sujit Vakkalanka,1 Andrew Zhao,1 Mohammed Samannodi2

    Primary Hyperaldosteronism: a Case of Unilateral Adrenal Hyperplasia with Contralateral Incidentaloma Sujit Vakkalanka,1 Andrew Zhao,1 Mohammed Samannodi2

    Unexpected outcome (positive or negative) including adverse drug reactions CASE REPORT Primary hyperaldosteronism: a case of unilateral adrenal hyperplasia with contralateral incidentaloma Sujit Vakkalanka,1 Andrew Zhao,1 Mohammed Samannodi2 1University at Buffalo, Buffalo, SUMMARY palpitations or any difficulty breathing in the past. New York, USA Primary hyperaldosteronism is one of the most common She was being managed in an outpatient setting for 2Department of Medicine, Buffalo, New York, USA causes of secondary hypertension but clear hypokalaemia and hypertension since 2009. She differentiation between its various subtypes can be a has been taking three antihypertensives (amlodi- Correspondence to clinical challenge. We report the case of a 37-year-old pine, benazepril and labetalol) and supplemental Dr Mohammed Samannodi, African-American woman with refractory hypertension potassium (2 tablets of 10 mEq three times a day) [email protected] who was admitted to our hospital for palpitations, but was very recently switched to hydralazine, ver- Accepted 28 June 2016 shortness of breath and headache. Her laboratory results apamil and doxazosin mesylate, and two potassium showed hypokalaemia and an elevated aldosterone/renin tablets of 20 mEq three times a day. ratio. An abdominal CT scan showed a nodule in the left On physical examination, her heart rate was adrenal gland but adrenal venous sampling showed 110 bpm while the blood pressure was 170/ elevated aldosterone/renin ratio from the right adrenal 110 mm Hg. Cardiac, abdominal, neurological and vein. The patient began a new medical regimen but musculoskeletal examinations were unimpressive declined any surgical options. We recommend with no signs of clubbing or oedema.
  • Monogenic Forms of Mineralocorticoid Hypertension: Insights Into the Pathogenesis of ‘Essential’ Hypertension?

    Monogenic Forms of Mineralocorticoid Hypertension: Insights Into the Pathogenesis of ‘Essential’ Hypertension?

    Journal of Human Hypertension (1998) 12, 7–12 1998 Stockton Press. All rights reserved 0950-9240/98 $12.00 REVIEW ARTICLE Monogenic forms of mineralocorticoid hypertension: insights into the pathogenesis of ‘essential’ hypertension? M Petrelli and PM Stewart Department of Medicine, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK Keywords: hyperaldosteronism; mineralocorticoid; Liddle’s syndrome; inheritance; cortisol; 11␤-hydroxysteroid dehydrogen- ase Hypertension is a common condition, which, mary aldosteronism due to an adrenocortical tumour depending on its definition, affects 10–25% of the (Conn’s Syndrome).1 Both subjects had a mineral- population. Because it is an established risk factor ocorticoid excess syndrome, characterised by pot- for coronary and cerebrovascular disease, hyperten- assium deficiency, suppressed plasma renin activity sion has, quite rightly, been targeted as an important (PRA) and increased aldosterone secretion rate, factor in determining the health of the nation. which, in contrast to tumorous aldosteronism, Despite this we can explain the underlying cause of responded to treatment with the synthetic glucocort- a patient’s hypertension in Ͻ5% of cases; the icoid, dexamethasone. Shortly afterwards, an remainder are labelled ‘essential’ hypertension, an additional, well-documented case was described, elegant way of stating that the aetiology is unknown. confirming the existence of this new ‘glucocorticoid As a result, in the vast majority of cases treatment remediable’ aldosteronism syndrome.2 Sub- is given on an empirical basis. sequently it was shown to be inherited in an autoso- In the last 5 years, significant advances have been mal dominant fashion and approximately 100 cases made in our understanding of the pathogenesis of were reported in the world literature up to the early hypertension with the characterisation of three 1990’s.3–9 forms of inherited hypertension.
  • Quantification of Hair Corticosterone, DHEA and Testosterone As

    Quantification of Hair Corticosterone, DHEA and Testosterone As

    animals Article Quantification of Hair Corticosterone, DHEA and Testosterone as a Potential Tool for Welfare Assessment in Male Laboratory Mice Alberto Elmi 1 , Viola Galligioni 2, Nadia Govoni 1 , Martina Bertocchi 1 , Camilla Aniballi 1 , Maria Laura Bacci 1 , José M. Sánchez-Morgado 2 and Domenico Ventrella 1,* 1 Department of Veterinary Medical Sciences, University of Bologna, 40064 Ozzano dell’Emilia, BO, Italy; [email protected] (A.E.); [email protected] (N.G.); [email protected] (M.B.); [email protected] (C.A.); [email protected] (M.L.B.) 2 Comparative Medicine Unit, Trinity College Dublin, D02 Dublin, Ireland; [email protected] (V.G.); [email protected] (J.M.S.-M.) * Correspondence: [email protected]; Tel.: +39-051-2097-926 Received: 11 November 2020; Accepted: 14 December 2020; Published: 16 December 2020 Simple Summary: Mice is the most used species in the biomedical research laboratory setting. Scientists are constantly striving to find new tools to assess their welfare, in order to ameliorate husbandry conditions, leading to a better life and scientific data. Steroid hormones can provide information regarding different behavioral tracts of laboratory animals but their quantification often require stressful sampling procedures. Hair represents a good, less invasive, alternative in such scenario and is also indicative of longer timespan due to hormones’ accumulation. The aim of the work was to quantify steroid hormones in the hair of male laboratory mice and to look for differences imputable to age and housing conditions (pairs VS groups). Age influenced all analysed hormones by increasing testosterone and dehydroepiandrosterone (DHEA) levels and decreasing corticosterone.
  • Adrenal Insufficiency Immunodeficiency Sy in a Patient Ndrome

    Adrenal Insufficiency Immunodeficiency Sy in a Patient Ndrome

    Endocrine Journal 1994, 41(1), 13-18 Adrenal Insufficiency in a Patient with Acquired Immunodeficiency Sy ndrome KoIcHI FUJII, IsAO MORIMOTO, ATSUSHIWAKE, YOHSUKEOKADA, NoBUo INOKUCHI, OsAMUISHIDA, YOIcHIRONAKANO, SUSUMUODA, ANDSUMIYA ETO First Departmento f Internal Medicine,University of Occupational and EnvironmentalHealth, Kitakyushu807, Japan Abstract. A 46-year-old man was admitted because of hypotension and consciousness disturbance. He was a patient with hemophilia B, and diagnosed as having an AIDS-related complex 2 years prior to admission. On admission he had severe hyponatremia. Hormonal studies revealed that he had Addison's disease. Serum cytomegalovirus (CMV) antibody titers were high, and a CMV antigen was detected in his urine, which suggested CMV adrenalitis caused by an active CMV infection. After the administration of hydrocortisone and ganciclovir, his general clinical condition and biochemical test results were back to normal. However, the adrenal dysfunction was irreversible, despite the treatment with ganciclovir. With an increase in the number of AIDS patients, we have to consider adrenal insuffi- ciency due to a CMV infection in patients with AIDS. Key words: Acquired Immunodeficiency Syndrome (AIDS), Cytomegalovirus infection, Adrenal Insuffi- ciency, Addison's Disease. (Endocrine Journal 41:13-18,1994) AUTOPSY reports of acquired immunodeficiency syndrome (AIDS) patients have noted adrenal de- Methods structive lesions associated with a cytomegalovirus (CMV) infection [1-5]. These reports indicate that Plasma aldosterone [8] and plasma renin activity more than 50% of AIDS patients have a various de- (PRA) [9] were measured with a radioimmunoas- grees of CMV adrenalitis. However, few cases say (RIA) kit (Daichi Radioisotope Ltd., Tokyo, Ja- have shown presented clinical and biochemical pan).
  • Failing Hormones

    Failing Hormones

    PHoto qu iZ failing hormones F.L. Opdam1*, B.E.P.B. Ballieux2, H. Guchelaar3, A.M. Pereira1 Departments of 1Internal Medicine and Endocrinology, 2Clinical Chemistry, 3Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands, *corresponding author: e-mail: [email protected] Case reP ort A 70-year-old female patient presented to the outpatient Sodium concentration was 126 mmol/l, potassium 4.9 clinic with general malaise, salt craving, and hypotension. mmol/l, creatinine 59 umol/l and plasma osmolality She had been treated for severe asthma with 15 mg 244 mOsm/kg. Urinary sodium concentration was 43 prednisone daily without interruptions for at least ten mmol/l. ACTH was suppressed (<5 ng/l), with a normal years. This treatment was complicated by the development afternoon cortisol level (0.293 mg/l). Plasma renin activity of diabetes mellitus and severe osteoporosis. In addition, was undetectable (<0.10 mg/l/hour), and aldosterone she suffered from generalised myopathy and skeletal pain, concentration was low (0.13 nmol/l, reference range 0.0 to for which she took naproxen 500 mg three times a day. 0.35 nmol/l). The transtubular potassium gradient (TTPG = (Urine potassium/ (urine osmol/serum osmol))/ serum On clinical examination, a wheel-chair dependent, 71-year- potassium)) was 3.7 (reference >7) old woman was seen with a moon face, buffalo hump, abdominal fat accumulation, and severe muscle atrophy (figure 1). Her blood pressure, however, was low (110/60), WHat is yo Ur dia Gnosis? both in supine and in upright position. See page 532 for the answer to this photo quiz.
  • Appendix: Common Steroid Identification—GC-MS Mass Spectra

    Appendix: Common Steroid Identification—GC-MS Mass Spectra

    Appendix: Common Steroid Identification—GC-MS Mass Spectra Gary Woodward, Francis Lam, and Gill Rumsby As described in Chap. 3, steroid profiling in the context of steroidogenic conditions is performed by GC-MS analysis following conjugate hydrolysis and derivatisation. Below are the mass spectra used for identification of urine steroids described throughout this book, and compiled during routine practice within our laboratory. Steroids are given in approximate order of their retention times. Androstanediol (internal standard) % 100 129 256 346 107 241 331 436 215 287 372 484 516 569 637 677 0 100 150 200 250 300 350 400 450 500 550 600 650 70 Pregnadienol % 129 50 243 267 372 173 357 0 421 494 525 556 620 665 7 100 150 200 250 300 350 400 450 500 550 600 650 70 G. Woodward · G. Rumsby Department of Clinical Biochemistry, University College London Hospitals, London, UK F. Lam Level 2-Chemistry, Health Services Laboratories, London, UK © Springer International Publishing AG, part of Springer Nature 2019 177 G. Rumsby, G. M. Woodward (eds.), Disorders of Steroidogenesis, https://doi.org/10.1007/978-3-319-96364-8 178 Appendix: Common Steroid Identification—GC-MS Mass Spectra Androsterone % 100 270 360 107 147 213 253 362 0 434 461 546 610 687 100 150 200 250 300 350 400 450 500 550 600 650 700 Aetiocholanolone % 100 270 360 105 131 213 422 0 255 362 460 506 564 644 679 100 150 200 250 300 350 400 450 500 550 600 650 700 Dehydroepiandrosterone % 100 129 268 260 358 105 374 0 211 432 459 523 592 642 682 7 100 150 200 250 300 350 400 450 500
  • A Guide to Understanding the Steroid Pathway: New Insights and Diagnostic Implications

    A Guide to Understanding the Steroid Pathway: New Insights and Diagnostic Implications

    Clinical Biochemistry 47 (2014) 5–15 Contents lists available at ScienceDirect Clinical Biochemistry journal homepage: www.elsevier.com/locate/clinbiochem A guide to understanding the steroid pathway: New insights and diagnostic implications Ronda F. Greaves a,b,⁎,GaneshJevalikarc, Jacqueline K. Hewitt b,d,e, Margaret R. Zacharin b,d,e a School of Medical Sciences, RMIT University, Victoria, Australia b Murdoch Children's Research Institute, Melbourne, Australia c Medanta Medicity Hospital, Gurgaon Haryana, India d Department of Endocrinology & Diabetes, The Royal Children's Hospital, Victoria, Australia e Department of Paediatrics, University of Melbourne, Victoria, Australia article info abstract Article history: Steroid analysis has always been complicated requiring a clear understanding of both the clinical and analytical Received 3 May 2014 aspects in order to accurately interpret results. The literature relating to this specialised area spans many decades Received in revised form 17 July 2014 and the intricacies of the steroid pathway have evolved with time. A number of key changes, including discovery Accepted 19 July 2014 of the alternative androgen pathway, have occurred in the last decade, potentially changing our understanding Available online 31 July 2014 and approach to investigating disorders of sexual development. Such investigation usually occurs in specialised paediatric centres and although preterm infants represent only a small percentage of the patient population, Keywords: Steroid pathways consideration of the persistence of the foetal adrenal zone is an additional important consideration when under- Alternative steroid pathway taking steroid hormone investigations. The recent expanded role of mass spectrometry and molecular diagnostic Tissue specific steroid metabolism methods provides significant improvements for accurate steroid quantification and identification of enzyme Steroid methods deficiencies.
  • Glucocorticoid-Remediable Aldosteronism

    Glucocorticoid-Remediable Aldosteronism

    CME Review Article #18 0021-972X/2001/1104-0263 The Endocrinologist Copyright © 2001 by Lippincott Williams & Wilkins CHIEF EDITOR’S NOTE: This article is the 18th of 36 that will be published in 2001 for which a total of up to 36 Category 1 CME credits can be earned. Instructions for how credits can be earned appear following the Table of Contents. Glucocorticoid-Remediable Aldosteronism Robert G. Dluhy, M.D.* Glucocorticoid-remediable aldosteronism (GRA) eralocorticoid-excess state. GRA is caused by a represents a rare, heriditary form of primary aldos- chimeric gene duplication that results from unequal teronism which is inherited in an autosomal domi- crossing over between the highly homologous 11␤- nant fashion. GRA is characterized by early onset hydroxylase (CYP11B1) and aldosterone synthase of moderate-to-severe hypertension and suppressed (CYP11B2) genes. The chimeric gene represents a plasma renin activity. The family history is often fusion of the 5'adrenocorticotropin-responsive reg- positive for a history of early hemorrhagic stroke. ulatory region of the 11␤-hydroxylase gene and the However, the clinical and biochemical features that 3' coding sequence of the aldosterone synthase define mineralcorticoid excess states, such as hy- gene. This results in ectopic expression of aldos- pokalemia, are not consistently present in GRA. terone synthase activity in the zona fasciculata, the Accordingly, recognition of this syndrome can be zone of the adrenal gland that normally secretes difficult. In GRA, aldosterone secretion is solely cortisol. This mutation explains the physiology and regulated by adrenocorticotropin. As a result, the genetics of GRA and provides the basis for a simple administration of exogenous glucocorticoids will direct genetic test for this disorder.
  • The First Reported Case of Hyperreninemic Hypoaldosteronism Due to Mucopolysaccharidosis Disorder

    The First Reported Case of Hyperreninemic Hypoaldosteronism Due to Mucopolysaccharidosis Disorder

    Open Access Case Report DOI: 10.7759/cureus.8487 The First Reported Case of Hyperreninemic Hypoaldosteronism Due to Mucopolysaccharidosis Disorder Antony Gayed 1 , Valerie A. Schott 2 , Laura Meltzer 3 1. Vascular and Interventional Radiology, Medical University of South Carolina, Charleston, USA 2. Obstetrics and Gynecology, OhioHealth Riverside Methodist Hospital, Columbus, USA 3. Pediatrics, Rush University Children's Hospital, Chicago, USA Corresponding author: Antony Gayed, [email protected] Abstract Mucopolysaccharidoses (MPS) are rare genetic lysosomal storage disorders caused by a deficiency of enzymes that catalyze the breakdown of glycosaminoglycans. MPS-III, also known as Sanfilippo syndrome, is caused by a deficiency of one of four enzymes that catalyze heparan sulfate proteoglycan degradation. MPS-IIIA results from a deficiency of heparan sulfatase. The natural history of MPS-IIIA is marked by progressive neurodegeneration. A nine-year-old boy with developmental delay presented with progressive three-month functional decline culminating in emergency department presentation for lethargy and immobility. Laboratory workup revealed hepatic and renal failure, coagulopathy, pancytopenia, hypernatremia, and uremia requiring emergent dialysis. He developed hyperkalemia during the second month of hospitalization, the workup of which led to a diagnosis of hyperreninemic hypoaldosteronism with normal cortisol. Blood chemistry consistent with renal hypoperfusion prompted exploration of adrenal ischemia, specifically affecting the zona glomerulosa and sparing the zona fasciculata, to explain low aldosterone with normal cortisol. Heparan sulfate (HS) normally acts as a storage site for basic fibroblast growth factor (bFGF), a paracrine stimulator of aldosterone, but accumulates in MPS-IIIA due to deficiency of heparan sulfatase. If bFGF is sequestered in HS deposits in MPS-III, then paracrine signaling is reduced, accounting for the state of hypoaldosteronism.
  • Transient Pseudohypoaldosteronism in Childrens Secondary to Urinary

    Transient Pseudohypoaldosteronism in Childrens Secondary to Urinary

    ology hr & Nasser et al., J Nephrol Ther 2019, 9:5 p Th e e N r f a o p l e a u Journal of n t r i c u s o J ISSN: 2161-0959 Nephrology & Therapeutics CaseResearch Series Article OpenOpen Access Access Transient Pseudohypoaldosteronism in Childrens Secondary to Urinary Tract Infection: Literature Review and Report of 2 Cases Nasser S1, Nasser H1, Michael J2, Soboh S3, Ehsan N1, Shhadi S1, Boshra N3 and Nasser W3* 1Department of Pediatrics, Azrieli Faculty of Medicine, Baruch Padeh Poriya Medical Center, Lower Galilee, Israel 2Department of Radiology, Azrieli Faculty of Medicine, Baruch Padeh Poriya Medical Center, Lower Galilee, Israel 3Nephrology and Hypertension Division, Azrieli Faculty of Medicine, Baruch-Padeh Poriya Medical Center, Lower Galilee, Israel Abstract Pseudohypoaldosteronism (PHA) types I and II share hyperkalemia as a predominant finding. PHA is a heterogeneous syndrome characterized by a lack of response of the organs to the mineralocorticoid, and therefore there is loss of salts. Heredity can be autosomal dominant or recessive. It is very rare for other mutations to occur. Autosomal dominant PHA-I is characterized by mutations in the mineralocorticoid receptor, while Autosomal recessive PHA-I results from mutations in the epithelial sodium channel (ENaC). Clinical expression of renal PHA-I is variable: patients present with salt loss in the neonatal period, failure to thrive, vomiting, and dehydration. Symptoms of renal PHA-I often improve in early childhood and older children. PHA-II is the result of mutations in a family of serine-threonine kinases called with- no-lysine kinases (WNK) 1 and WNK4.